Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy
Mavacamten therapy was associated with marked haemodynamic and symptomatic improvements and a reduction in the ESC-based SCD risk in obstructive HCM. While these findings need to be confirmed and were not paralleled by a reduction in arrhythmic events, they suggest that myosin inhibition may influence arrhythmic risk stratification. Prospective studies with longer follow-up are required to determine whether such favourable remodelling translates into true arrhythmic protection.
Authors
- Romain Itier
- Pauline Fournier (ORCID: https://orcid.org/0000-0002-4916-5004)
- Miloud Cherbi (ORCID: https://orcid.org/0009-0004-8952-6283)
- Adrien Al Wazzan (ORCID: https://orcid.org/0000-0001-7356-6134)
- Claire Huang Lucas
- Gilbert Habib
- N. Cohen
- P. Usai
- Erwan Donal
- Eve Cariou
- Olivier Lairez
- Damien Eyharts
Institutions
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Université Rennes 2 (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Centre Hospitalier de la Côte Basque (FR)
- Université de Rennes (FR)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1093/eschf/xvag003
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00